Next Article in Journal
Exploring the Therapeutic Potential of Gene Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy
Previous Article in Journal
The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas
Previous Article in Special Issue
Detection of ER Stress in iPSC-Derived Neurons Carrying the p.N370S Mutation in the GBA1 Gene
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 6
10.3390/biomedicines12061350
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases

by
Dong-Hun Lee
1,
Eun Chae Lee
2,
Ji young Lee
3,
Man Ryul Lee
4,
Jae-won Shim
4,5,* and
Jae Sang Oh
3,*
1
Industry-Academic Cooperation Foundation, The Catholic University of Korea, 222, Banpo-daro, Seocho-gu, Seoul 06591, Republic of Korea
2
Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
3
Department of Neurosurgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
4
Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan-si 31151, Republic of Korea
5
Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-si 31151, Republic of Korea
*
Authors to whom correspondence should be addressed.
Biomedicines 2024, 12(6), 1350; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12061350
Submission received: 20 April 2024 / Revised: 5 June 2024 / Accepted: 14 June 2024 / Published: 18 June 2024
(This article belongs to the Special Issue Pluripotent Stem Cell: Current Understanding and Future Directions)
Browse Figures
Versions Notes

Abstract

:
Current chemical treatments for cerebrovascular disease and neurological disorders have limited efficacy in tissue repair and functional restoration. Induced pluripotent stem cells (iPSCs) present a promising avenue in regenerative medicine for addressing neurological conditions. iPSCs, which are capable of reprogramming adult cells to regain pluripotency, offer the potential for patient-specific, personalized therapies. The modulation of molecular mechanisms through specific growth factor inhibition and signaling pathways can direct iPSCs’ differentiation into neural stem cells (NSCs). These include employing bone morphogenetic protein-4 (BMP-4), transforming growth factor-beta (TGFβ), and Sma-and Mad-related protein (SMAD) signaling. iPSC-derived NSCs can subsequently differentiate into various neuron types, each performing distinct functions. Cell transplantation underscores the potential of iPSC-derived NSCs to treat neurodegenerative diseases such as Parkinson’s disease and points to future research directions for optimizing differentiation protocols and enhancing clinical applications.

1. Introduction

Neurological disorders, especially cerebrovascular diseases and strokes, are a significant global issue [1]. These conditions lead to irreversible neural damage, and currently, there are limited effective treatments available for repairing damaged tissue or restoring function [2,3,4]. To overcome this, regenerative medicine has begun to focus on the differentiation of neural cells from induced pluripotent stem cells (iPSCs) [5].
Stem cells inherently possess two key functions: the capacity for unlimited self-renewal and the ability to differentiate into one or more specialized cell types [6]. These characteristics play a fundamental role in exploring tissue repair and disease treatment methods through stem cells [7].
iPSCs are cells that have regained pluripotency through the reprogramming of already differentiated mature cells and are created by manipulating the expression of specific genes [8,9]. The technology of iPSCs, which restores pluripotency from mature cells, offers innovative potential for generating patient-specific disease models and developing personalized treatments [10]. Neural cells generated from iPSCs can be used to replace or repair damaged neural tissue [11]. Moreover, using neural cells differentiated from patient-derived iPSCs allows for effective testing of new drugs’ efficacy or toxicity [12]. Transplanting these iPSC-derived neural cells could lead to functional recovery in neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease.
Against this background, it is expected that the process of neuronal differentiation of iPSCs will be examined, and the mechanisms of neuronal differentiation will be elucidated, providing an important step in the development of regenerative medicine and disease therapies.

2. Inhibiting the SMAD Pathway in iPSCs for Neural Differentiation

The process of differentiating iPSCs into various cells includes several complex signaling pathways and molecular mechanisms. iPSCs have important advantages over embryonic stem cells (ESCs). iPSCs are derived from adult cells; they bypass the ethical issues of destroying embryos to derive ESCs [13,14]. iPSCs can be self-derived from the patient, allowing for the creation of patient-specific cell lines [12,15]. They can differentiate into multiple cell types, allowing drug testing to assess effectiveness and identify side effects safely and efficiently [16]. Furthermore, iPSCs retain the same pluripotency as that of ESCs [17]. Both iPSCs and ESCs exhibited equivalent neuronal differentiation potential, and both cells showed similar cholinergic motor neuron differentiation potential and the ability to induce the contraction of myotubes [18]. In another study, while iPSC-derived neural stem cells (NSCs) had decreased ATP production compared to that of ESC-derived NSCs, iPSC-derived astrocytes had increased ATP production compared to that of ESC-derived astrocytes [19].
Specifically, the differentiation of neuronal cells is induced by the dual inhibition of the Sma- and Mad-related protein (SMAD) pathway (Figure 1). Before understanding the SMAD pathway, it is necessary to understand the transforming growth factor-beta (TGFβ) signaling pathway, which includes SMAD.

2.1. SMAD Pathway Inhibition

Inhibition of the SMAD pathway directs the fate of iPSCs towards the neuroectoderm and induces neural cell differentiation through the inhibition of TGFβ and BMP-4 signaling, as mentioned above [20]. For the dual inhibition of the SMAD pathway, SB431542 is used to inhibit the TGFβ pathway and Noggin is used to inhibit the BMP pathway.
SB431542 inhibits the Lefty/Activin/TGFβ pathway by blocking the phosphorylation of ALK4, ALK5, and ALK7 receptors. SB431542 also inhibits differentiation to the mesoderm by inhibiting Activin/Nodal signaling. Noggin inhibits differentiation to the ectoderm by inhibiting the BMP pathway. A combined treatment of SB431542 and Noggin induced the neural differentiation of stem cells with high efficiency [20]. The mechanisms by which Noggin and SB431542 induced neural cell differentiation include Activin- and Nanog-mediated network destabilization [21], BMP-induced inhibition of differentiation [22], and the inhibition of mesodermal and endodermal differentiation through the inhibition of endogenous Activin and BMP signaling [23,24]. Treatment with SB431542 decreases Nanog expression and significantly increases CDX2 expression. The inhibition of CDX2 in the presence of Noggin or SB431542 demonstrates that one of the key roles of Noggin is the inhibition of endogenous BMP signaling, which induces trophoblast fate during differentiation.

2.2. TGFβ Signaling Pathway

The TGFβ signaling pathway is a pathway that regulates cell growth, differentiation, migration, death, and homeostasis [25]. The superfamily of TGFβ includes bone morphogenetic protein (BMP), Activin, Nodal, and TGFβ. Signal transduction in this pathway begins with the binding of superfamily ligands of TGFβ to TGFβ receptor type II and TGFβ receptor type I [26]. Activated TGFβ receptors recruit Smad2/3 for TGFβ and activation signaling [27] and form complexes of CoSmad and R-smad, such as Smad4, for BMP signaling [28]. Smad complexes accumulate in the nucleus and are directly involved in the transcriptional regulation of target genes [29].

2.3. BMP Signaling Pathway

BMPs are cytokines that belong to a group of growth factors [30]. BMPs have a role in early skeletal formation during embryonic development and were originally known to act as bone growth factors [31]. BMPs bind to a heteromeric receptor complex composed of type I and type II serine/threonine kinase receptors, which are received by different activin receptors and BMP receptors [32]. The two receptors are highly homologous and can activate both Smad and non-Smad signaling.
BMP-4 is a member of the BMP superfamily, which induces the ventral mesoderm to establish dorsal–ventral morphogenesis. BMP4 signaling is found in the formation of early mesoderm and germ cells, and the development of the lungs and liver is attributed to BMP4 signaling [33]. Inhibition of this BMP-4 signaling induces neurogenesis and the formation of the neural plate. Indeed, the knockout of BMP-4 in mice resulted in little mesodermal differentiation [34].

2.4. RA Pathway

Retinoic acid (RA) is a molecule that contributes to the development and homeostasis of the nervous system [35]. The RA signaling depends on cells having the ability to metabolize retinol. Transcription is regulated by the binding of RA to its receptor, RA receptor (RAR), which forms a complex with the retinoid X receptor (RXR) [36]. The RA is involved in the differentiation of NSCs into neurons, astrocytes, or oligodendrocytes [37]. RA activates the Hox gene, which is required for hindbrain development and regulates the head–trunk transition [38]. RA is required for the formation of primary neurons [39]. In an embryonal carcinoma cell line in vitro, RA promoted neurite outgrowth and stimulated the expression of neural differentiation markers [40].
Furthermore, RA is essential in embryonic development and is essential for the development of many organs, including the hindbrain, spinal cord, skeleton, heart, and brain [41].

2.5. BDNF, GDNF, and NGF Pathway Regulation

Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor found primarily in the brain and central nervous system that regulates nerve cell survival, growth, and neurotransmission [42]. BDNF promotes neuronal survival and growth in dorsal root ganglion cells and in hippocampal and cortical neurons [43,44]. In in vitro experiments in which neural differentiation was induced in a variety of stem cells, neural differentiation was confirmed after treatment with BDNF [45,46].
Glial-cell-line-derived neurotrophic factor (GDNF) is a protein that promotes the survival of many different neurons [47]. GDNF can be secreted by neurons and peripheral cells during development, including astrocytes, and interacts with GDNF family receptor alpha 1 and 2 [48]. In particular, it has a protective effect on dopamine-producing nerve cells, making it an important target in neurodegenerative diseases such as Parkinson’s disease [49].
Nerve growth factor (NGF) is a neuropeptide involved in regulating the growth, proliferation, and survival of neurons [50]. In in vivo and in vitro studies, NGF has been shown to have an important role in the differentiation and survival of neurons, as well as in the protection of degenerating neurons.

3. Differentiation of Various Neural Cells from iPSCs

Through various mechanisms, neural cell differentiation from iPSCs can develop a diverse array of neurons (Figure 2, Table 1). It is possible to consider prior studies that successfully differentiated various neurons from iPSCs and the application of protocols used for the differentiation of human ESCs (hESCs) into iPSCs.

3.1. Differentiation into Cortical Neurons

iPSCs can differentiate into cortex neurons. The study by Kaveena Autar [51] induced an initial neural lineage in iPSCs using two small molecule inhibitors of the SMAD pathway, LDN193189 and SB431542, promoting neuroepithelial differentiation. Following the early neural induction, the neural epithelium was induced using DKK-1, a Wnt/B antagonist, and DMH-1, a BMP inhibitor, enhancing the development of rostral neuroepithelial cells. Finally, the application of cyclopamine, an SHH inhibitor, designated the cortex fate, while BDNF, GDNF, cAMP, ascorbic acid, and laminin improved the generation of cortical neurons.
In the research by Yichen Shi, cortical development was induced in both hESCs and iPSCs using dorsomorphin, an inhibitor of the SMAD pathway [52].
Cortical differentiation can be confirmed by the reduced expression of the pluripotency gene Oct4 and the increased expression of the genes Tbr1, CTIP2, Satb2, Brn2, and Cux1.

3.2. Differentiation into Dopaminergic Neurons

Human iPSCs are capable of differentiating into midbrain dopaminergic neurons. In a study by Lixiang Ma, dopaminergic neurons were generated from iPSCs [53]. After inducing iPSCs into neural epithelial cells, applying FGF8 and SHH efficiently produced dopaminergic neurons from midbrain precursors without the need for co-culture. Dopaminergic neurons can be identified by detecting markers such as TH, TUJ-1, LMX1A, FOXA2, and NURR1.
It is also possible to induce the dopaminergic neuronal differentiation of iPSCs without the use of pharmacological compounds for the inhibition of SMAD mechanisms [54]. Adeno-associated viral vectors were designed to upregulate Lmx1a through SHH and Wnt and then transfected into iPSCs. The iPSCs not only successfully generated dopaminergic neurons but also showed a consistent number of them.

3.3. Differentiation into Motor Neurons

iPSCs can differentiate into motor neurons [55]. After inducing iPSCs into embryonic bodies, treatment with RA and purmorphamine, an activator of the sonic hedgehog pathway, resulted in the expression of neural precursor markers. Cells forming neural rosettes were mechanically separated, plated in media containing RA and Shh, and cultured for a week. Following further culture with BDNF, CTNF, GDNF, and Shh, after 3–5 weeks, cells displayed motor neuron characteristics, and BIII-tubulin, ChAT, and Islet1 were detected.

3.4. Differentiation into Astrocytes

iPSCs can differentiate into astrocytes [56]. iPSCs induced into NSCs were cultured in NSC media containing B27, BMP, CTNF, and bFGF. The differentiated astrocytes were co-cultured with the neuron layer. Throughout the culture, neurons were distinguished by their distinct cell bodies and measured along axons using fluorescence imaging. Neurons and astrocytes, as well as oligodendrocytes, were differentiated by expressing markers such as BIII-tubulin, GFAP, and GalC.

3.5. Differentiation into Oligodendrocytes

iPSCs can differentiate into oligodendrocytes [57]. Neural differentiation was induced through dual SMAD inhibition. After differentiation, adding SAG and RA promoted sphere aggregation, and using PDGF media encouraged OPC formation. The development of oligodendrocytes was confirmed through the detection of OLIG2, MAP2, and SOX10.

3.6. Differentiation into Hippocampal Neurons

NSCs derived from iPSCs can differentiate into the hippocampus [58]. Neural induction media composed of B27, N2, and NEAA were supplemented with LDN-193189, Cyclopamine, SB431542, and XAV-939 to induce differentiation, and CHIR-99021 and BDNF were added to promote hippocampal neuron development. The generation of hippocampal neurons was confirmed through the detection of PROX1.

3.7. Differentiation into Serotonergic Neurons

NSCs derived from iPSCs can differentiate into serotonergic neurons [59]. Human pluripotent stem cells (hPSCs) were cultured in an N2 medium combined with a knockout serum replacement medium and treated with SB431542, LDN193189, purmorphamine, and RA. After 11 days, the medium was switched to NB/B27 medium, and BDNF was added. Following differentiation, the presence of serotonergic neurons was confirmed through immunofluorescence staining for 5-HT, MAP2, TUJ1, FEV, and TPH2 expression. Subsequent 3D culture also successfully yielded organoids, and the release of 5-HT and its metabolites was observed.

4. Therapeutic Research Using Neural Cells Derived from iPSCs

Researchers are hopeful that the transplantation of neural cells derived from iPSCs can overcome neurodegenerative diseases. To treat Parkinson’s disease, which has been identified as a disorder of dopaminergic neurons, the transplantation of iPSC-derived dopaminergic neurons is considered. If these transplanted neurons function normally, they could potentially cure Parkinson’s disease. This anticipation has led to the execution of cell transplantation therapies targeting either cells or animals, and in some cases, applications have extended to clinical trials.

4.1. Dopaminergic Neuron Therapy in a Model of Parkinson’s Disease

Dopaminergic neurons from PSCs may be a candidate for the treatment of Parkinson’s disease. When dopaminergic neurons were transplanted into the nigrostriatal lesions of rats with Parkinson’s disease, the neurons survived and interacted in the rats’ brains for a long period of time [60]. After cell transplantation, the rats’ motor function was restored.

4.2. In Vivo Transplantation and Survival of Astrocytes

Astrocytes derived from PSCs were transplanted into the striatum of mice to investigate their survival and function [56]. In the brains of mice obtained 2 weeks after astrocyte transplantation, GFAP-positive cells were still observed.
Furthermore, when iPSC-derived astrocyte progenitors were transplanted into the brain of an Alzheimer’s disease model in mice and examined through immunostaining, they interacted and functionally integrated with other cells in vivo [61].

4.3. Survival of Oligodendrocytes after Transplantation in Mice

To investigate the function of iPSC-derived oligodendrocytes, cells were injected into the forebrain of immunocompromised mice. At 12 weeks after cell injection, the oligodendrocytes were detected through immunofluorescence staining of hNA+ and OLIG2 protein in the corpus callosum.

4.4. Clinical Trials with iPSC Transplantation

There are very few studies in which iPSCs have been transplanted into humans. This is because questions about the safety, stability, and efficacy of iPSCs are constantly being raised. The first thing that researchers worry about is the ability to form tumors, which is a common concern in stem cell research [62]. iPSCs also have a theoretical risk of forming tumors, so safety considerations follow. In addition, treatments using iPSC technology may result in modifications to the human genome, which requires discussion of the long-term ethical implications. For example, concerns include human cloning or human–animal chimeras.
On the other side of the spectrum, there are also concerns related to the immune response. Even though iPSCs are self-derived cells, the immune system may recognize them as foreign and attack them [63,64]. This can happen mainly due to mismatches in human leukocyte antigens (HLAs), which is why it is important to select cells based on HLA matching. If iPSCs are generated from a donor with a specific HLA type, it is possible to use iPSCs from other people [63]. If an HLA is incompatible, one can also modulate HLA expression or use gene editing [64].
Finally, because iPSCs must undergo reverse differentiation from human-derived cells, it takes a significant amount of time just to generate the cells. This can make it difficult to use autologous cells to treat acute illnesses.
In 2020, a transplantation study of iPSC-derived dopamine progenitor cells for the treatment of Parkinson’s disease patients was conducted [65]. After harvesting fibroblasts by skin biopsy, dopamine progenitor cells were characterized in vitro with dopamine-neuron-specific and other neuronal markers. Characterized dopamine progenitor cells were transplanted into patients with Parkinson’s disease, and Parkinson’s-disease-related measures were assessed at 1, 3, 6, 9, and 12 months and every 6 months thereafter. Transplanted cells survived for 2 years without side effects. F-DOPA PET-CT imaging from 0 to 24 months showed a modest increase in dopamine uptake in the posterior cingulate near the implantation site. They also showed improved quality of life in clinical assessments of motor signs in Parkinson’s disease, although interpretation should be carried out with caution due to the lack of a control group comparison.
In 2021, there was a planned clinical study of the transplantation of iPSC-derived neural progenitor cells for the treatment of subacute complete spinal cord injury [66]. However, this was postponed due to the sudden onset of the COVID-19 pandemic. A clinical-grade iPSC line (YZWJs513) prepared at the GMP facility of Osaka National Hospital was induced to differentiate into neural progenitor cells (NPCs), and preclinical studies using mouse models confirmed its promotion of motor function recovery after spinal cord injury.

5. Conclusions

iPSCs can differentiate into a variety of neuronal cell types, including dopaminergic neurons, astrocytes, and microglia, which could be a revolutionary way to treat a variety of neurodegenerative diseases. Inhibition of TGFβ and the SMAD pathway induces neural progenitor cell differentiation of cells with restored pluripotency. The differentiated cells still survive and function in the body.
The chemical drugs used to treat neurodegenerative diseases have different susceptibilities in different patients and have short half-lives, meaning that they are quickly used up by the body. Drugs for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease can slow their progression by increasing the release of neurotransmitters, but they cannot reverse the course of the disease. In addition, unlike a body part such as an arm, it is very difficult to accurately deliver chemical drugs to the brain. Cell transplantation treatments using patient-derived iPSCs are entirely patient-derived, have a high degree of tolerance, and may be able to survive and function in the long term to reverse the progression of neurodegenerative diseases.
However, clinical experimental studies of iPSCs and neural progenitor cells differentiated from them are extremely rare and require careful handling. The response in experimental animals and humans may be different, and we do not yet fully understand the differentiation of iPSCs.
Future research should focus on optimizing protocols for iPSC-derived neural cell differentiation, ensuring long-term viability and the functional integration of transplanted cells in vivo and paving the way for clinical applications.

Author Contributions

Conceptualization: J.S.O.; Data curation: D.-H.L., E.C.L., J.y.L. and M.R.L.; Funding acquisition: J.S.O.; Project administration: J.S.O.; Visualization: D.-H.L.; Writing—original draft: D.-H.L., J.-w.S. and J.S.O.; Writing—review and editing: D.-H.L., J.-w.S. and J.S.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Bio and Medical Technology Development Program of the National Research Foundation funded by the Korean government (2023RA1A2C100531), by a grant from the Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health and Welfare, Republic of Korea (HC22C0043), and by a grant from the Korean Fund for Regenerative Medicine (KFRM) funded by the Korean government (KFRM-2022-00070557). The authors wish to acknowledge the financial support of the Catholic University of Korea Uijeongbu and the St. Mary’s Hospital Clinical Research Laboratory Foundation.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

BDNFBrain-derived neurotrophic factor
BMPBone morphogenetic protein
ESCEmbryonic stem cell
GDNFGlial-cell-line-derived neurotrophic factor
HLAHuman leukocyte antigen
iPSCInduced pluripotent stem cell
NPCNeural progenitor cell
NSCNeural stem cell
PSCPluripotent stem cell
RARetinoic acid
RARRetinoic acid receptor
RXRRetinoid X receptor
SMADSma- and Mad-related protein
TGFβTransforming growth factor-beta

References

  1. Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Anderson, C.A.M.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Beaton, A.Z.; Boehme, A.K.; Buxton, A.E.; et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation 2023, 147, e93–e621. [Google Scholar] [CrossRef] [PubMed]
  2. Zhang, X.; Shu, B.; Zhang, D.; Huang, L.; Fu, Q.; Du, G. The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. CNS Neurol. Disord. Drug Targets 2018, 17, 509–521. [Google Scholar] [CrossRef] [PubMed]
  3. Czlonkowska, A.; Lesniak, M. Pharmacotherapy in stroke rehabilitation. Expert Opin. Pharmacother. 2009, 10, 1249–1259. [Google Scholar] [CrossRef] [PubMed]
  4. Chollet, F.; Cramer, S.C.; Stinear, C.; Kappelle, L.J.; Baron, J.C.; Weiller, C.; Azouvi, P.; Hommel, M.; Sabatini, U.; Moulin, T.; et al. Pharmacological therapies in post stroke recovery: Recommendations for future clinical trials. J. Neurol. 2014, 261, 1461–1468. [Google Scholar] [CrossRef]
  5. Neaverson, A.; Andersson, M.H.L.; Arshad, O.A.; Foulser, L.; Goodwin-Trotman, M.; Hunter, A.; Newman, B.; Patel, M.; Roth, C.; Thwaites, T.; et al. Differentiation of human induced pluripotent stem cells into cortical neural stem cells. Front. Cell Dev. Biol. 2022, 10, 1023340. [Google Scholar] [CrossRef] [PubMed]
  6. He, S.; Nakada, D.; Morrison, S.J. Mechanisms of stem cell self-renewal. Annu. Rev. Cell Dev. Biol. 2009, 25, 377–406. [Google Scholar] [CrossRef] [PubMed]
  7. Biehl, J.K.; Russell, B. Introduction to stem cell therapy. J. Cardiovasc. Nurs. 2009, 24, 98–103. [Google Scholar] [CrossRef] [PubMed]
  8. Zakrzewski, W.; Dobrzynski, M.; Szymonowicz, M.; Rybak, Z. Stem cells: Past, present, and future. Stem Cell Res. Ther. 2019, 10, 68. [Google Scholar] [CrossRef] [PubMed]
  9. Chehelgerdi, M.; Behdarvand Dehkordi, F.; Chehelgerdi, M.; Kabiri, H.; Salehian-Dehkordi, H.; Abdolvand, M.; Salmanizadeh, S.; Rashidi, M.; Niazmand, A.; Ahmadi, S.; et al. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Mol. Cancer 2023, 22, 189. [Google Scholar] [CrossRef]
  10. Adhya, D.; Swarup, V.; Nagy, R.; Dutan, L.; Shum, C.; Valencia-Alarcon, E.P.; Jozwik, K.M.; Mendez, M.A.; Horder, J.; Loth, E.; et al. Atypical Neurogenesis in Induced Pluripotent Stem Cells From Autistic Individuals. Biol. Psychiatry 2021, 89, 486–496. [Google Scholar] [CrossRef]
  11. Liou, R.H.; Edwards, T.L.; Martin, K.R.; Wong, R.C. Neuronal Reprogramming for Tissue Repair and Neuroregeneration. Int. J. Mol. Sci. 2020, 21, 4273. [Google Scholar] [CrossRef] [PubMed]
  12. Paik, D.T.; Chandy, M.; Wu, J.C. Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. Pharmacol. Rev. 2020, 72, 320–342. [Google Scholar] [CrossRef] [PubMed]
  13. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282, 1145–1147. [Google Scholar] [CrossRef] [PubMed]
  14. Baldwin, T. Morality and human embryo research. Introduction to the Talking Point on morality and human embryo research. EMBO Rep. 2009, 10, 299–300. [Google Scholar] [CrossRef] [PubMed]
  15. Jang, J.; Yoo, J.E.; Lee, J.A.; Lee, D.R.; Kim, J.Y.; Huh, Y.J.; Kim, D.S.; Park, C.Y.; Hwang, D.Y.; Kim, H.S.; et al. Disease-specific induced pluripotent stem cells: A platform for human disease modeling and drug discovery. Exp. Mol. Med. 2012, 44, 202–213. [Google Scholar] [CrossRef] [PubMed]
  16. Elitt, M.S.; Barbar, L.; Tesar, P.J. Drug screening for human genetic diseases using iPSC models. Hum. Mol. Genet. 2018, 27, R89–R98. [Google Scholar] [CrossRef] [PubMed]
  17. Choi, J.; Lee, S.; Mallard, W.; Clement, K.; Tagliazucchi, G.M.; Lim, H.; Choi, I.Y.; Ferrari, F.; Tsankov, A.M.; Pop, R.; et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat. Biotechnol. 2015, 33, 1173–1181. [Google Scholar] [CrossRef]
  18. Marei, H.E.; Althani, A.; Lashen, S.; Cenciarelli, C.; Hasan, A. Genetically unmatched human iPSC and ESC exhibit equivalent gene expression and neuronal differentiation potential. Sci. Rep. 2017, 7, 17504. [Google Scholar] [CrossRef]
  19. Kristiansen, C.K.; Chen, A.; Hoyland, L.E.; Ziegler, M.; Sullivan, G.J.; Bindoff, L.A.; Liang, K.X. Comparing the mitochondrial signatures in ESCs and iPSCs and their neural derivations. Cell Cycle 2022, 21, 2206–2221. [Google Scholar] [CrossRef]
  20. Chambers, S.M.; Fasano, C.A.; Papapetrou, E.P.; Tomishima, M.; Sadelain, M.; Studer, L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009, 27, 275–280. [Google Scholar] [CrossRef]
  21. Xu, R.H.; Sampsell-Barron, T.L.; Gu, F.; Root, S.; Peck, R.M.; Pan, G.; Yu, J.; Antosiewicz-Bourget, J.; Tian, S.; Stewart, R.; et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008, 3, 196–206. [Google Scholar] [CrossRef] [PubMed]
  22. Xu, R.H.; Chen, X.; Li, D.S.; Li, R.; Addicks, G.C.; Glennon, C.; Zwaka, T.P.; Thomson, J.A. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat. Biotechnol. 2002, 20, 1261–1264. [Google Scholar] [CrossRef]
  23. D’Amour, K.A.; Agulnick, A.D.; Eliazer, S.; Kelly, O.G.; Kroon, E.; Baetge, E.E. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat. Biotechnol. 2005, 23, 1534–1541. [Google Scholar] [CrossRef]
  24. Laflamme, M.A.; Chen, K.Y.; Naumova, A.V.; Muskheli, V.; Fugate, J.A.; Dupras, S.K.; Reinecke, H.; Xu, C.; Hassanipour, M.; Police, S.; et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25, 1015–1024. [Google Scholar] [CrossRef]
  25. Massague, J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 1990, 6, 597–641. [Google Scholar] [CrossRef] [PubMed]
  26. Massague, J.; Chen, Y.G. Controlling TGF-beta signaling. Genes Dev. 2000, 14, 627–644. [Google Scholar] [CrossRef] [PubMed]
  27. Chen, X.; Xu, L. Mechanism and regulation of nucleocytoplasmic trafficking of smad. Cell Biosci. 2011, 1, 40. [Google Scholar] [CrossRef]
  28. Tang, L.Y.; Zhang, Y.E. Non-degradative ubiquitination in Smad-dependent TGF-beta signaling. Cell Biosci. 2011, 1, 43. [Google Scholar] [CrossRef]
  29. Schmierer, B.; Hill, C.S. TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 2007, 8, 970–982. [Google Scholar] [CrossRef]
  30. Reddi, A.H.; Reddi, A. Bone morphogenetic proteins (BMPs): From morphogens to metabologens. Cytokine Growth Factor Rev. 2009, 20, 341–342. [Google Scholar] [CrossRef]
  31. Sieber, C.; Kopf, J.; Hiepen, C.; Knaus, P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009, 20, 343–355. [Google Scholar] [CrossRef]
  32. Miyazono, K.; Maeda, S.; Imamura, T. Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 2004, 23, 4232–4237. [Google Scholar] [CrossRef] [PubMed]
  33. Nilsson, E.E.; Skinner, M.K. Bone morphogenetic protein-4 acts as an ovarian follicle survival factor and promotes primordial follicle development. Biol. Reprod. 2003, 69, 1265–1272. [Google Scholar] [CrossRef]
  34. Winnier, G.; Blessing, M.; Labosky, P.A.; Hogan, B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995, 9, 2105–2116. [Google Scholar] [CrossRef]
  35. Tan, B.T.; Wang, L.; Li, S.; Long, Z.Y.; Wu, Y.M.; Liu, Y. Retinoic acid induced the differentiation of neural stem cells from embryonic spinal cord into functional neurons in vitro. Int. J. Clin. Exp. Pathol. 2015, 8, 8129–8135. [Google Scholar]
  36. Kurokawa, R.; Soderstrom, M.; Horlein, A.; Halachmi, S.; Brown, M.; Rosenfeld, M.G.; Glass, C.K. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995, 377, 451–454. [Google Scholar] [CrossRef]
  37. Mosher, K.I.; Schaffer, D.V. Proliferation versus Differentiation: Redefining Retinoic Acid’s Role. Stem Cell Rep. 2018, 10, 1673–1675. [Google Scholar] [CrossRef] [PubMed]
  38. Lee, K.; Skromne, I. Retinoic acid regulates size, pattern and alignment of tissues at the head-trunk transition. Development 2014, 141, 4375–4384. [Google Scholar] [CrossRef] [PubMed]
  39. Sharpe, C.; Goldstone, K. The control of Xenopus embryonic primary neurogenesis is mediated by retinoid signalling in the neurectoderm. Mech. Dev. 2000, 91, 69–80. [Google Scholar] [CrossRef]
  40. Maden, M.; Holder, N. Retinoic acid and development of the central nervous system. Bioessays 1992, 14, 431–438. [Google Scholar] [CrossRef]
  41. Clagett-Dame, M.; DeLuca, H.F. The role of vitamin A in mammalian reproduction and embryonic development. Annu. Rev. Nutr. 2002, 22, 347–381. [Google Scholar] [CrossRef] [PubMed]
  42. Binder, D.K.; Scharfman, H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22, 123–131. [Google Scholar] [CrossRef] [PubMed]
  43. Acheson, A.; Conover, J.C.; Fandl, J.P.; DeChiara, T.M.; Russell, M.; Thadani, A.; Squinto, S.P.; Yancopoulos, G.D.; Lindsay, R.M. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 1995, 374, 450–453. [Google Scholar] [CrossRef] [PubMed]
  44. Huang, E.J.; Reichardt, L.F. Neurotrophins: Roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24, 677–736. [Google Scholar] [CrossRef] [PubMed]
  45. Ahmed, S.; Reynolds, B.A.; Weiss, S. BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors. J. Neurosci. 1995, 15, 5765–5778. [Google Scholar] [CrossRef]
  46. Lim, J.Y.; Park, S.I.; Oh, J.H.; Kim, S.M.; Jeong, C.H.; Jun, J.A.; Lee, K.S.; Oh, W.; Lee, J.K.; Jeun, S.S. Brain-derived neurotrophic factor stimulates the neural differentiation of human umbilical cord blood-derived mesenchymal stem cells and survival of differentiated cells through MAPK/ERK and PI3K/Akt-dependent signaling pathways. J. Neurosci. Res. 2008, 86, 2168–2178. [Google Scholar] [CrossRef]
  47. Airaksinen, M.S.; Saarma, M. The GDNF family: Signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3, 383–394. [Google Scholar] [CrossRef] [PubMed]
  48. Cik, M.; Masure, S.; Lesage, A.S.; Van Der Linden, I.; Van Gompel, P.; Pangalos, M.N.; Gordon, R.D.; Leysen, J.E. Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J. Biol. Chem. 2000, 275, 27505–27512. [Google Scholar] [CrossRef] [PubMed]
  49. Matlik, K.; Garton, D.R.; Montano-Rodriguez, A.R.; Olfat, S.; Eren, F.; Casserly, L.; Damdimopoulos, A.; Panhelainen, A.; Porokuokka, L.L.; Kopra, J.J.; et al. Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Mol. Psychiatry 2022, 27, 3247–3261. [Google Scholar] [CrossRef]
  50. Aloe, L.; Rocco, M.L.; Balzamino, B.O.; Micera, A. Nerve Growth Factor: A Focus on Neuroscience and Therapy. Curr. Neuropharmacol. 2015, 13, 294–303. [Google Scholar] [CrossRef]
  51. Autar, K.; Guo, X.; Rumsey, J.W.; Long, C.J.; Akanda, N.; Jackson, M.; Narasimhan, N.S.; Caneus, J.; Morgan, D.; Hickman, J.J. A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders. Stem Cell Rep. 2022, 17, 96–109. [Google Scholar] [CrossRef]
  52. Shi, Y.; Kirwan, P.; Livesey, F.J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 2012, 7, 1836–1846. [Google Scholar] [CrossRef]
  53. Ma, L.; Liu, Y.; Zhang, S.C. Directed differentiation of dopamine neurons from human pluripotent stem cells. Methods Mol. Biol. 2011, 767, 411–418. [Google Scholar] [CrossRef] [PubMed]
  54. Mahajani, S.; Raina, A.; Fokken, C.; Kugler, S.; Bahr, M. Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. Cell Death Dis. 2019, 10, 898. [Google Scholar] [CrossRef] [PubMed]
  55. Karumbayaram, S.; Novitch, B.G.; Patterson, M.; Umbach, J.A.; Richter, L.; Lindgren, A.; Conway, A.E.; Clark, A.T.; Goldman, S.A.; Plath, K.; et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009, 27, 806–811. [Google Scholar] [CrossRef] [PubMed]
  56. Shaltouki, A.; Peng, J.; Liu, Q.; Rao, M.S.; Zeng, X. Efficient generation of astrocytes from human pluripotent stem cells in defined conditions. Stem Cells 2013, 31, 941–952. [Google Scholar] [CrossRef]
  57. Douvaras, P.; Wang, J.; Zimmer, M.; Hanchuk, S.; O’Bara, M.A.; Sadiq, S.; Sim, F.J.; Goldman, J.; Fossati, V. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Rep. 2014, 3, 250–259. [Google Scholar] [CrossRef]
  58. Pomeshchik, Y.; Klementieva, O.; Gil, J.; Martinsson, I.; Hansen, M.G.; de Vries, T.; Sancho-Balsells, A.; Russ, K.; Savchenko, E.; Collin, A.; et al. Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem Cell Rep. 2020, 15, 256–273. [Google Scholar] [CrossRef]
  59. Valiulahi, P.; Vidyawan, V.; Puspita, L.; Oh, Y.; Juwono, V.B.; Sittipo, P.; Friedlander, G.; Yahalomi, D.; Sohn, J.W.; Lee, Y.K.; et al. Generation of caudal-type serotonin neurons and hindbrain-fate organoids from hPSCs. Stem Cell Rep. 2021, 16, 1938–1952. [Google Scholar] [CrossRef]
  60. Yang, D.; Zhang, Z.J.; Oldenburg, M.; Ayala, M.; Zhang, S.C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008, 26, 55–63. [Google Scholar] [CrossRef]
  61. Preman, P.; Tcw, J.; Calafate, S.; Snellinx, A.; Alfonso-Triguero, M.; Corthout, N.; Munck, S.; Thal, D.R.; Goate, A.M.; De Strooper, B.; et al. Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-beta plaques. Mol. Neurodegener. 2021, 16, 68. [Google Scholar] [CrossRef]
  62. Moradi, S.; Mahdizadeh, H.; Saric, T.; Kim, J.; Harati, J.; Shahsavarani, H.; Greber, B.; Moore, J.B.t. Research and therapy with induced pluripotent stem cells (iPSCs): Social, legal, and ethical considerations. Stem Cell Res. Ther. 2019, 10, 341. [Google Scholar] [CrossRef] [PubMed]
  63. Flahou, C.; Morishima, T.; Takizawa, H.; Sugimoto, N. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice with NK Cell Immunity. Front. Immunol. 2021, 12, 662360. [Google Scholar] [CrossRef] [PubMed]
  64. Otsuka, R.; Wada, H.; Murata, T.; Seino, K.I. Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflamm. Regen. 2020, 40, 12. [Google Scholar] [CrossRef] [PubMed]
  65. Schweitzer, J.S.; Song, B.; Herrington, T.M.; Park, T.Y.; Lee, N.; Ko, S.; Jeon, J.; Cha, Y.; Kim, K.; Li, Q.; et al. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson’s Disease. N. Engl. J. Med. 2020, 382, 1926–1932. [Google Scholar] [CrossRef]
  66. Sugai, K.; Sumida, M.; Shofuda, T.; Yamaguchi, R.; Tamura, T.; Kohzuki, T.; Abe, T.; Shibata, R.; Kamata, Y.; Ito, S.; et al. First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol. Regen. Ther. 2021, 18, 321–333. [Google Scholar] [CrossRef]
Biomedicines 12 01350 g001
Figure 1. Adding reprogramming factors to PBMCs to induce their reverse differentiation into iPSCs. Reverse-differentiated iPSCs can be induced to undergo mesoderm or endoderm differentiation through the activation of the SMAD pathway. Inhibition of the SMAD pathway induces the neural stem cell differentiation of iPSCs. BMP: bone morphogenetic protein, TGFβ: transforming growth factor-beta, NSC: neural stem cell, iPSC: induced pluripotent stem cell, PBMC: peripheral blood mononuclear cell, OSKM: Oct4/Sox2/Klf4/c-Myc, SMAD: Sma- and Mad-related protein.
Figure 1. Adding reprogramming factors to PBMCs to induce their reverse differentiation into iPSCs. Reverse-differentiated iPSCs can be induced to undergo mesoderm or endoderm differentiation through the activation of the SMAD pathway. Inhibition of the SMAD pathway induces the neural stem cell differentiation of iPSCs. BMP: bone morphogenetic protein, TGFβ: transforming growth factor-beta, NSC: neural stem cell, iPSC: induced pluripotent stem cell, PBMC: peripheral blood mononuclear cell, OSKM: Oct4/Sox2/Klf4/c-Myc, SMAD: Sma- and Mad-related protein.
Biomedicines 12 01350 g001
Biomedicines 12 01350 g002
Figure 2. Different neural cells that can differentiate from neural stem cells. Cells induced to become neural stem cells due to the inhibition of the dual SMAD pathway with SB431542 and Noggin can be combined to add cytokines specific to each differentiation target. The cytokines described next to the black arrows indicate the fate of each neuron. Differentiated neurons are identified through the detection of the proteins listed under each neuron.
Figure 2. Different neural cells that can differentiate from neural stem cells. Cells induced to become neural stem cells due to the inhibition of the dual SMAD pathway with SB431542 and Noggin can be combined to add cytokines specific to each differentiation target. The cytokines described next to the black arrows indicate the fate of each neuron. Differentiated neurons are identified through the detection of the proteins listed under each neuron.
Biomedicines 12 01350 g002
Table 1. Strategies for iPSCs differentiated into neural progenitor cells to become multifunctional neurons.
Table 1. Strategies for iPSCs differentiated into neural progenitor cells to become multifunctional neurons.
ReferencesType of NeuronDifferentiation InducersSpecific Markers
[51,52]Cortical NeuronsCyclopamine, DKK-1, DMH-1, BDNF, GDNF, cAMP, Ascorbic acid, LamininTbr1, CTIP2, Satb2, Brn2, Cux1
[53,54]Dopaminergic NeuronsFGF8, SHHTH, TUJ-1, LMX1A, FOXA2, NURR1
[55]Motor NeuronsGDNF, CTNF, BDNF, SHH, RABIII-tubulin, ChAT, Islet1
[56]AstrocytesB27, BMP, CTNF, bFGFGFAP, GalC, BIII-tubulin
[57]OligodendrocytesPDGF, RA, SAGOLIG2, MAP2, SOX10
[58]Hippocampal NeuronsCHIR, BDNF, Cyclopamine, XAVPROX1, MAP2
[59]Serotonergic NeuronsPurmophamine, BDNF, RA5-HT, MAP2
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, D.-H.; Lee, E.C.; Lee, J.y.; Lee, M.R.; Shim, J.-w.; Oh, J.S. Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases. Biomedicines 2024, 12, 1350. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12061350

AMA Style

Lee D-H, Lee EC, Lee Jy, Lee MR, Shim J-w, Oh JS. Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases. Biomedicines. 2024; 12(6):1350. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12061350

Chicago/Turabian Style

Lee, Dong-Hun, Eun Chae Lee, Ji young Lee, Man Ryul Lee, Jae-won Shim, and Jae Sang Oh. 2024. "Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases" Biomedicines 12, no. 6: 1350. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12061350

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop